Home
/
ENANTA PHARMACEUTICALS INC
/
Financials
/
Quarterly
ENANTA PHARMACEUTICALS INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ENANTA PHARMACEUTICALS INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2018
Mar 31, 2018
$44.05M
May 10, 2018
Q1
2018
Dec 31, 2017
$38.11M
Feb 9, 2018
Q3
2017
Jun 30, 2017
$7.51M
Aug 9, 2017
Q2
2018
Mar 31, 2017
$8.96M
May 10, 2018
Q1
2018
Dec 31, 2016
$10.42M
Feb 9, 2018
Q3
2017
Jun 30, 2016
$13.98M
Aug 9, 2017
Q2
2017
Mar 31, 2016
$13.00M
May 10, 2017
Q1
2017
Dec 31, 2015
$48.45M
Feb 9, 2017
Q3
2016
Jun 30, 2015
$11.60M
Aug 9, 2016
Q2
2016
Mar 31, 2015
$57.37M
May 10, 2016
Q1
2016
Dec 31, 2014
$77.50M
Feb 9, 2016
Q3
2015
Jun 30, 2014
$42.05M
Aug 10, 2015
Q2
2015
Mar 31, 2014
$2.16M
May 8, 2015
Q1
2015
Dec 31, 2013
$893.0K
Feb 6, 2015
Q3
2014
Jun 30, 2013
$1.65M
Aug 12, 2014
Q2
2014
Mar 31, 2013
$1.20M
May 12, 2014
Q1
2014
Dec 31, 2012
$27.86M
Feb 13, 2014
Q3
2013
Jun 30, 2012
$2.54M
Aug 12, 2013
Q2
2013
Mar 31, 2012
$36.57M
May 15, 2013
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
$18.62M
Feb 11, 2026
Q3
2025
Jun 30, 2025
$18.31M
Aug 13, 2025
Q2
2025
Mar 31, 2025
$14.93M
May 14, 2025
Q1
2026
Dec 31, 2024
$16.96M
Feb 11, 2026
Q3
2025
Jun 30, 2024
$17.97M
Aug 13, 2025
Q2
2025
Mar 31, 2024
$17.05M
May 14, 2025
Q1
2024
Dec 31, 2023
$18.00M
Feb 12, 2025
Q3
2024
Jun 30, 2023
$18.89M
Aug 7, 2024
Q2
2024
Mar 31, 2023
$17.80M
May 8, 2024
Q1
2024
Dec 31, 2022
$23.59M
Feb 8, 2024
Q3
2023
Jun 30, 2022
$19.48M
Aug 8, 2023
Q2
2023
Mar 31, 2022
$18.72M
May 9, 2023
Q1
2023
Dec 31, 2021
$27.65M
Feb 8, 2023
Q3
2022
Jun 30, 2021
$21.62M
Aug 8, 2022
Q2
2022
Mar 31, 2021
$20.13M
May 9, 2022
Q1
2022
Dec 31, 2020
$31.74M
Feb 10, 2022
Q3
2021
Jun 30, 2020
$18.65M
Aug 9, 2021
Q2
2021
Mar 31, 2020
$27.62M
May 10, 2021
Q1
2021
Dec 31, 2019
$52.57M
Feb 9, 2021
Q3
2020
Jun 30, 2019
$44.37M
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
($11.94M)
Feb 11, 2026
Q1
2026
Sep 30, 2025
($81.89M)
Feb 11, 2026
Q3
2025
Jun 30, 2025
($18.26M)
Aug 13, 2025
Q2
2025
Mar 31, 2025
($22.64M)
May 14, 2025
Q3
2025
Mar 31, 2025
($22.64M)
Aug 13, 2025
Q2
2025
Dec 31, 2024
($22.29M)
May 14, 2025
Q3
2025
Dec 31, 2024
($22.29M)
Aug 13, 2025
Q1
2026
Dec 31, 2024
($22.29M)
Feb 11, 2026
Q2
2025
Sep 30, 2024
($116.05M)
May 14, 2025
Q1
2024
Sep 30, 2024
($116.05M)
Feb 12, 2025
Q3
2025
Sep 30, 2024
($116.05M)
Aug 13, 2025
Q3
2025
Jun 30, 2024
($22.66M)
Aug 13, 2025
Q3
2025
Mar 31, 2024
($31.16M)
Aug 13, 2025
Q2
2025
Mar 31, 2024
($31.16M)
May 14, 2025
Q1
2024
Dec 31, 2023
($33.41M)
Feb 12, 2025
Q2
2025
Dec 31, 2023
($33.41M)
May 14, 2025
Q3
2025
Dec 31, 2023
($33.41M)
Aug 13, 2025
Q1
2024
Sep 30, 2023
($133.82M)
Feb 8, 2024
Q2
2024
Sep 30, 2023
($133.82M)
May 8, 2024
Q3
2024
Sep 30, 2023
($133.82M)
Aug 7, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Dec 31, 2025
($11.25M)
Feb 11, 2026
Q3
2025
Jun 30, 2025
($18.89M)
Aug 13, 2025
Q2
2025
Mar 31, 2025
($24.53M)
May 14, 2025
Q1
2026
Dec 31, 2024
($23.54M)
Feb 11, 2026
Q3
2025
Jun 30, 2024
($24.19M)
Aug 13, 2025
Q2
2025
Mar 31, 2024
($32.77M)
May 14, 2025
Q1
2024
Dec 31, 2023
($34.89M)
Feb 12, 2025
Q3
2024
Jun 30, 2023
($36.71M)
Aug 7, 2024
Q2
2024
Mar 31, 2023
($39.45M)
May 8, 2024
Q1
2024
Dec 31, 2022
($30.01M)
Feb 8, 2024
Q3
2023
Jun 30, 2022
($32.54M)
Aug 8, 2023
Q2
2023
Mar 31, 2022
($33.85M)
May 9, 2023
Q1
2023
Dec 31, 2021
($30.41M)
Feb 8, 2023
Q3
2022
Jun 30, 2021
($33.85M)
Aug 8, 2022
Q2
2022
Mar 31, 2021
($29.70M)
May 9, 2022
Q1
2022
Dec 31, 2020
($12.30M)
Feb 10, 2022
Q3
2021
Jun 30, 2020
($22.85M)
Aug 9, 2021
Q2
2021
Mar 31, 2020
($11.88M)
May 10, 2021
Q1
2021
Dec 31, 2019
$12.87M
Feb 9, 2021
Q3
2020
Jun 30, 2019
$3.76M
Aug 10, 2020